EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies

Jennifer Nash iD, Mohammed N Meah iD, Beth Whittington iD, Samuel Debono iD, Jennifer Raftis, Mark R Miller iD, Andrew Sorbie, Nicholas L Mills iD, Josselin Nespoux, Lorraine Bruce, Rodger Duffin, Neeraj Dhaun iD und 10 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024

DOI: 10.1161/atvbaha.123.320448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von Jennifer Nash und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.N., M.N.M., B.W., S.D., J.R., M.R.M., A.S., N.L.M., J.N., L.B., R.D., N…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Thrombosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: BMS-986141 is a novel potent highly selective antagonist of PAR (protease-activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus formation in isolation and in combination with factor Xa inhibition in high shear conditions in healthy people. We sought to determine whether PAR4 antagonism had additive antithrombotic effects in patients with coronary artery disease who were receiving antiplatelet therapy. METHODS: Forty-five patients with stable coronary heart disease and 10 healthy volunteers completed a phase 2a open-label 4-arm single-center study. Patients were allocated to 1 of 3 treatment arms for 7 days: (1) ticagrelor (90 mg BID), (2) aspirin (75 mg QD), or (3) the combination of ticagrelor and aspirin. Agonist-induced platelet aggregation, platelet activation, and ex vivo thrombus formation were measured before and 2 and 24 hours after a single oral 4-mg dose of BMS-986141 on the first study visit day in all participants. RESULTS: BMS-986141 demonstrated highly selective inhibition of PAR4-AP (agonist peptide)–induced platelet aggregation, P-selectin expression, and platelet-monocyte aggregate expression ( P ≤0.001 for all), which were unaffected by concomitant antiplatelet therapies. PAR4 antagonism reduced ex vivo thrombus area in high shear conditions in healthy volunteers (−21%; P =0.001) and in patients receiving ticagrelor alone (−28%; P =0.001), aspirin alone (−23%; P =0.018), or both in combination (−24%; P ≤0.001). Plasma concentration of BMS-986141 correlated with PAR4-AP–induced platelet responses ( P ≤0.001 for all) and total thrombus area under high shear stress conditions ( P ≤0.01 for all). CONCLUSIONS: PAR4 antagonism has additive antithrombotic effects when used in addition to ticagrelor, aspirin, or their combination, in patients with stable coronary heart disease. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05093790.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseThrombosisHumansPlatelet Aggregation InhibitorsTicagrelorFibrinolytic AgentsAspirinPlatelet AggregationBlood Platelets

Stichwörter der Autor:innen

aspirincoronary artery diseaseplatelet activationplatelet aggregationthrombosisticagrelor

Substanzen

Platelet Aggregation InhibitorsTicagrelorFibrinolytic AgentsAspirin

Autor:innen und Institutionen

  • Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (J.N., M.N.M., B.W., S.D., J.R., M.R.M., A.S., N.L.M., J.N., L.B., R.D., N.D., M.B., D.E.N.).
  • WorldWide Patient Safety (B.W.), Bristol Myers Squibb, Lawrenceville, NJ.
  • Clinical Pharmacology and Pharmacometrics (L.C., S.M.), Bristol Myers Squibb, Lawrenceville, NJ.
  • Translational Medicine (M.K., Z.W.), Bristol Myers Squibb, Lawrenceville, NJ.
  • Early Cardiovascular Clinical Development, R&D (M.K.), Bristol Myers Squibb, Lawrenceville, NJ.
  • Global Biometrics and Data Sciences (Y.Z., S.J.), Bristol Myers Squibb, Lawrenceville, NJ.

ORCID-Profile: Jennifer Nash, Mohammed N Meah, Beth Whittington, Samuel Debono, Mark R Miller, Nicholas L Mills, Neeraj Dhaun, Samira Merali, Zhaoqing Wang, David E Newby

Förderung

  • British Heart Foundation

Zitieren

APA

Nash, J., Meah, M. N., Whittington, B., Debono, S., Raftis, J., Miller, M. R., Sorbie, A., Mills, N. L., Nespoux, J., Bruce, L., Duffin, R., Dhaun, N., Brittan, M., Chao, L., Merali, S., Kim, M., Wang, Z., Zhang, Y., Jin, S., …, & Newby, D. E. (2024). PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.320448

Vancouver

Nash J, Meah MN, Whittington B, Debono S, Raftis J, Miller MR, et al. PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.123.320448

BibTeX
@article{Nash2024,
  author = {Nash, Jennifer and Meah, Mohammed N and Whittington, Beth and Debono, Samuel and Raftis, Jennifer and Miller, Mark R and Sorbie, Andrew and Mills, Nicholas L and Nespoux, Josselin and Bruce, Lorraine and Duffin, Rodger and Dhaun, Neeraj and Brittan, Mairi and Chao, Longfei and Merali, Samira and Kim, Minji and Wang, Zhaoqing and Zhang, Yue and Jin, Shiqiang and Wang, Beqing and Kozinn, Marc and Newby, David E},
  title = {PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  doi = {10.1161/atvbaha.123.320448}
}
Kostenlos starten →